Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation MarketBusiness Wire · Oct 5, 2026
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial OfficerBusiness Wire · Sep 14, 2026
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance SheetBusiness Wire · Aug 25, 2026Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.19 | -$0.10 | Beat |
| May 19, 2026 | -$0.15 | -$0.15 | Beat |
| Mar 26, 2026 | -$0.47 | -$0.47 | Beat |
| Nov 14, 2025 | -$0.11 | -$3.12 | Miss |
| Aug 14, 2025 | – | -$2.25 | |
| May 21, 2025 | – | $18.98 |